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Rapid pathologic and molecular 
diagnosis of lung cancer patients  
based on telepathology techniques
Szybka diagnostyka patomorfologiczna i molekularna 
chorych na raka płuca na podstawie techniki telepatologii
ABSTRACT
Telepathology is an emerging form of diagnostic process introducing digitalization of slides prepared from formalin-
-fixed paraffin-embedded materials and stained cytological smears. The use of whole slide imaging (WSI) systems 
could accelerate and improve the diagnosis of malignant neoplasms without the need of on-site pathologist or 
transporting diagnostic material in-between different locations. The implementation of endobronchial ultrasound 
(EBUS) and endoscopic ultrasound (EUS) with fine needle aspiration (FNA) in diagnostic process of advanced 
lung cancer creates a new field for telepathology utilization. In selected patients, pathomorphological and genetic 
diagnosis may take less than a week and therapeutic decisions can be made in a short time. There are several 
important issues that concern the use of telepathology and WSI in everyday clinical environment. This short review 
presents the pros and cons of this technology and its applicability in rapid diagnosis of lung cancer, its utilization 
in connection with novel sampling methods and molecular analysis.
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STRESZCZENIE
Telepatologia to nowa forma procesu diagnostycznego wprowadzająca cyfryzację preparatów przygotowanych 
z bloczków parafinowych lub wybarwionych rozmazów cytologicznych. Wykorzystanie systemu skanowania ca-
łych preparatów może polepszyć i znacząco przyspieszyć diagnostykę nowotworów złośliwych bez wymaganej 
obecności patomorfologa w miejscu wykonywania diagnostyki oraz bez potrzeby transportowania pobranego 
materiału pomiędzy różnymi lokalizacjami. Wprowadzenie biopsji aspiracyjnej cienkoigłowej (FNA) przeprowadza-
nej pod kontrolą przezoskrzelowego lub przezprzełykowego USG (EBUS lub EUS) do procesu diagnostycznego 
zaawansowanego raka płuca tworzy nowe pole do zastosowania telepatologii. U wybranych chorych diagnoza 
patomorfologiczna i genetyczna może trwać poniżej tygodnia, a decyzje terapeutyczne mogą zostać podjęte 
w krótkim czasie. Istnieje kilka istotnych kwestii związanych z wykorzystaniem telepatologii oraz skanowania całych 
preparatów w codziennej praktyce klinicznej. Ten krótki przegląd ma na celu przybliżenie wad i zalet opisanej 
technologii i ich możliwości wykorzystania w szybkiej diagnostyce raka płuca w połączeniu z nowoczesnymi 
metodami pobierania materiału i koniecznością prowadzenia diagnostyki genetycznej.
Słowa kluczowe: rak płuca, telepatologia, testy molekularne
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Introduction
Telepathology is an emerging form of diagnostic 
process introducing digitalization of stained cytological 
smears and slides prepared from formalin-fixed paraf-
fin-embedded (FFPE) tissues or cells (ethanol-fixed 
paraffin-embedded cells and fresh-frozen tissues are 
also acceptable) and its further analysis without the 
need of on-site pathologist or transporting diagnostic 
material in-between different locations. The use of 
novel techniques involving whole slide imaging (WSI) 
systems and remote robotic microscopy allows real-time 
consultation and diagnosis significantly accelerating 
further steps of treatment. It is especially important 
in case of areas without a skilled pathologist available, 
without a pathology laboratory or when a quick consult 
is needed. Such techniques might also be useful in edu-
cation and archiving of interesting cases, as well as in 
quality control of pathological analysis [1].
Whole slide imaging is a computer-based technique 
involving scanning of glass slides and converting them 
into digital images that may be accessible through special 
software and viewed later from any location in the World 
as long as it has Internet access. The image viewing 
software allows for previewing, zooming in and out or 
panning the whole picture, frequently with possibility 
of its analysis, adding annotations and comments on 
the image [1, 2].
WSI is still an expensive method, as it is a novel and 
freshly implemented technology. One of the main draw-
backs of WSI is the image size and analysis problems, as 
the scanned picture is created out of many high resolu-
tion and high magnification photos that create the whole 
slide picture. A common problem is also the speed of 
Internet connection and its capacity. Large size images 
need to be stored on servers and sent via fast streaming 
in order to maintain quality and speed of diagnosis. The 
other issue is the thickness of the slide which in case of 
cytology smears depends on skills of person performing 
the procedure and does not allow the analysis of dense 
clusters of cells, which may have the effect on diagnosis 
result. Highly specialized technicians should carefully 
prepare the slides (including material processing pro-
cedures and staining of cells or tissues). However, the 
analysis is a domain of a skilled pathologist. There are 
also no proper standards and validation options for this 
kind of technology and for different types of materials 
which makes it difficult to use in clinical setting. On the 
other hand scanning glass slides allows precious material 
to be prevented from transporting and risks of losing or 
destruction [2].
Apart of whole slide imaging there are other techni-
ques used in telepathology such as static image analysis 
or remote live video microscopy which allows patho-
logists to view the glass slides from a remote location 
without the need of personal appearance in the place 
where the procedure is being performed. Of course, 
a trained technician is necessary to operate the on-site 
microscope. The advantage is the possibility of live 
focusing on different plains of the smear, which is not 
possible in case of WSI. Its limitations are mostly con-
cerning the viewed image, as its choice in both methods 
depends on the person who operates the microscope and 
this persons’ judgment, hence — training. In contrast 
to WSI the image sent from the microscope represents 
only a part of the whole slide and a proper selection is 
necessary in order to prevent misdiagnoses [1].
In lung cancer patients, pathological examination 
becomes very fast, which allows genetic diagnostics 
and rapid therapeutic decision. This is particularly 
important for patients with advanced lung cancer qu-
alified for systemic therapy. The acceptable time from 
the start of the lung cancer diagnosis to start first-line 
treatment should not exceed one month. Ideally, the 
time to therapeutic decision should be less than two 
weeks. Trained technicians prepare hematoxylin and 
eosin (H+E) stained smears, scan the slides and share 
them with pathologists. In the absence of cancer cells 
in analyzed material, pathologist could immediately 
notify diagnosing physician. However, H+E stained 
slides are often sufficient to make a preliminary lung 
cancer diagnosis. Pathologist may order the use of hi-
stochemistry and immunohistochemistry (IHC) staining 
in case of diagnostic problems and in the event where 
quantity and quality of material archived in cell blocks 
is sufficient. In selected cases (non-squamous non-small 
cell lung cancer), in scanned H+E images, pathologist 
evaluates the percentage and localization of tumor cells 
and marks them for the purpose of macrodissection and 
molecular tests (EGFR gene mutations) [3]. 
Telepathology is also a way of archiving and creating 
large databases of scanned images for educational 
purposes and comparison analysis as the availability of 
normal and specific cases is usually a problem. There-
fore, the scanned images could be consulted by several 
pathologists, including those who specialize in unusual 
or rare cases [4].
Telepathology and telecytology, when compared 
to rapid on-site evaluation (ROSE) procedure, seem 
to have similar diagnosis results and are believed to be 
cost effective methods. The number of repeated pro-
cedures and the cost of maintaining on-site pathologist 
are reduced, as well as minimizing the time needed for 
material transportation between the place of procedure 
and pathology lab. If the team performing the endosco-
py/biopsy is trained in producing cytologic preparations 
it also reduces the time to preliminary diagnosis [5].
The use of WSI in Polish clinics is not common, as 
there are only two multicenter consortia that use this 
technology regularly. Although many hospitals and 
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universities already possess microscopic slide scanners, 
they are used for scientific purposes (computer image 
analysis, morphometry), didactic activities, archiving 
and consultation of rare or difficult cases. Pulmonary 
Hospital in Zakopane was the first center in Poland that 
utilized online diagnosis of digital microscopic slides 
in routine diagnostics. Since 2007, microscopic slides 
(initially only from intraoperative diagnoses, subsequ-
ently from fine-needle aspiration biopsies of tumors 
and metastatic lymph nodes) were examined by a team 
of five pathologists from Szczecin, Gliwice, Warszawa, 
Zabrze and Rzeszow. Similar system was implemented 
in Pulmonary Hospital in Bystra in 2010. Zakopane 
and Bystra centers utilized both scanners and dynamic 
microscopes. Same technology will soon also be imple-
mented in Department of Pneumonology, Oncology 
and Allergology in Lublin in conjunction with above 
mentioned centers. The Gliwice Branch of the Maria 
Sklodowska-Curie Memorial Cancer Center and Insti-
tute of Oncology leads the organization of the biggest 
telepathology project, meant to connect several Sile-
sian hospitals. Implementation of rapid diagnostic and 
treatment of malignant neoplasms enforces the use of 
telepathology techniques in Poland. It would allow for 
a diagnosis and treatment decision during one patients’ 
stay in hospital [6].
Use of WSI in clinic
The WHO classification of lung tumors was created 
on the basis of histological analysis of resected tissues, 
however in case of non-small cell lung cancer the majo-
rity of diagnosed cases present late stages of the disease, 
hence there are very limited surgery options and not 
many possibilities of acquiring histologic material. The-
refore the preliminary diagnosis is mostly given based 
on small biopsies and their picture, often accompanied 
by cytologic smears.
The current WHO classification of lung tumors 
puts a particular emphasis on the evaluation of small 
slices and cytology samples as a material which is the 
basis for lung cancer diagnosis. According to these new 
criteria, the diagnosis of adenocarcinoma (ADC) or 
squamous cell carcinoma (SCC) based on morpholo-
gical criteria in such samples can be made only when 
glandular differentiation or intracellular bridges and 
keratinization are visible. All other cases require ad-
ditional IHC staining. The WHO recommends using 
anti-TTF-1 antibodies to detect adenocarcinoma and 
anti-p40 for squamous cell carcinoma, however in ADC 
cases a co-expression of TTF-1 or napsin with squamous 
differentiation markers (p40, p63, CK5/6) is possible, 
whereas SCC cannot be described when the tumor cells 
present TTF-1 expression. Furthermore, a NSCLC NOS 
(non-otherwise specified) diagnosis should be presented 
when different cell populations presents both TTF-1 and 
p40 expression, with the annotation of adenosquamous 
carcinoma. It should also be noted that the IHC analysis 
in small biopsies only favors the diagnosis of the tumor 
type. The classification also contains recommendations 
to prepare 10 microscopic slides to avoid loss of mate-
rial during subsequent treatments of paraffin blocks in the 
microtome. These preparations may be used for standard 
pathological, IHC or molecular (also fluorescent in-situ 
hybridization — FISH) analysis. The panel of molecular 
tests included in the classification is very broad and goes 
beyond routinely used in Poland EGFR mutation testing. It 
is stressed that a confrontation of pathological and mo-
lecular diagnosis with radiologic image is crucial. There 
are also new recommendations for the pathological 
diagnosis of surgically resected lung cancer samples. In 
case of ADC the classification includes: preinvasive 
lesions (atypical adenomatous hyperplasia (AAH) and 
adenocarcinoma in-situ (AIS) (≤ 3 cm); minimally in-
vasive ADC (MIA) (≤ 3 cm with ≤ 5 mm invasion) and 
invasive ADC (G1: lepidic, G2: acinar, papillary and G3: 
micropapillary, solid). The classification limits the large 
cell carcinoma (LCC) diagnosis only to the cases when 
the morphological image is concomitant with negative 
mucin, TTF-1 and p40 staining. Some rare types of lung 
cancer are reclassified as ADC or SCC based on their 
IHC staining status. Among SCCs a basaloid carcinoma 
is introduced, which apart of characteristic morpholo-
gical image and lack of keratinization, presents positive 
staining for anti-p40 antibodies [7].
The implementation of endobronchial ultrasound 
(EBUS) and endoscopic ultrasound (EUS) with fine 
needle aspiration (FNA) in rapid diagnostic process of 
neoplasms creates a new field for telepathology utiliza-
tion. The ideal steps of the process would be (Figure 1):
1. Acquisition of sample material from EBUS/EUS-
-FNA.
2. Simultaneous, collection of cells to perform cells 
blocks (alcohol or formalin-fixed paraffin-embed-
ded) and creating glass smears.
3. Archiving cell blocks for further histochemistry and 
IHC examination as well as molecular tests (ALK 
gene rearrangement).
4. H+E staining of glass smears.
5. Scanning of the H+E stained smears and its analysis 
by a pathologist in remote location.
6. Preliminary diagnosis by the pathologist that would 
allow (if sufficient data is available) further dia-
gnostic steps or beginning of treatment to be taken 
almost instantly after the first diagnostic procedure.
7. In the case of diagnosis of non-squamous non-small 
cell lung cancer, evaluation of tumor cell percentage 
and localization (virtual marking) on H+E stained 
and scanned smears by pathologist.
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Figure 1. Algorithm for the diagnosis of lung cancer using EBUS/EUS FNA and telepathology procedures as well as genetic tests
Figure 2. Properly made cytology smear from EBUS FNA 
material
Figure 3. Incorrectly made cytology smear from EBUS FNA 
material
8. Transferring H+E stained slides to genetic labo-
ratory.
9. Tumor cells macrodissection based on scanned 
images.
10. DNA isolation from tumor-cell-enriched material.
11. EGFR gene mutations testing that would allow (if 
sufficient data is available) for further diagnostic or 
beginning of treatment steps to be taken 3–4 working 
days after the first diagnostic procedure.
12. Further examination of cell blocks in case of dia-
gnostic problems and necessity of further testing 
(including EGFR gene mutations and ALK gene 
rearrangement testing or testing for qualification 
to novel therapies in clinical trials).
The main advantage of this kind of rapid diagnostics 
is short time period between each decision being made 
and in the end a lot quicker treatment qualification of 
the patient. However it is important to note that in order 
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to this kind of diagnostic path to work properly a valid 
and coherent system of communication needs to be 
implemented between the technician, the pathologist, 
the surgeon/clinician/oncologist and molecular biologist. 
Obtaining high quality cytology smears depends on the 
skills of highly trained bronchoscopist (Figure 2 and 3). 
The samples gathered during EBUS/EUS-FNA proce-
dure also need to be fully pathologically analyzed after 
the procedure and the results need to be compared with 
the preliminary remote pathological diagnosis.
A very important issue is the amount of diagnostic 
material that is being obtained from the biopsy, as it has 
to be divided between few diagnostic stages — first of 
all the pathologic diagnosis, and later on the molecular 
analysis. Current knowledge and availability of molecu-
larly targeted therapies make it an important concern 
in case of NSCLC patients. The amount of cancer cells 
in the obtained material is crucial for molecular studies 
and the accuracy of diagnosis, which is why pathologists 
should pay attention to the amount of used material. 
Glass smears that are used to present a preliminary 
diagnosis may be the only source of cancer cells that 
are available for molecular analysis; hence the process 
of their digitalization is very important.
Legal issues of telepathology
Telepathology, mainly concerning whole slide ima-
ging, is more and more popular around the World with 
specific guidelines being created in order to carry viable 
diagnostic, consultation and education processes. The 
American Telemedicine Association (ATA) created 
such guidelines concerning technical, staff and Food 
and Drug Administration (FDA) issues. Similarly Ca-
nadian Association of Pathologists and British Royal 
College of Pathologists created such sets of rules and 
suggestions. These guidelines however do not consist 
of specific recommendations in methodology, as there 
are no validation data on the available equipment and 
no standards or best practices for specific equipment 
manufacturers. Each of the presented guidelines sug-
gests validation of the procedure inside the performing 
institution [8–10].
In Polish conditions a recently presented plan of 
rapid oncological diagnosis creates a niche where te-
lepathology fits perfectly. In order to give a quick and 
relevant diagnosis the presented techniques should 
be used on daily basis quickly connecting pathologists 
with molecular biologists and clinicians performing dia-
gnostic and therapeutic procedures. In large hospitals, 
where pathology labs are swarmed with samples from 
different clinics and of different origin, it is difficult 
to obtain quick answer to questions that arise during 
the surgical or diagnostic procedures that would allow 
easier and faster qualification of the patient for specific 
treatment, which in case of not only lung cancer but also 
other neoplasms is crucial.
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